Zhengye Biotechnology-AZYBT
13F holders, Q2 2026 (June 30)8holders
1new positions
1sold out
$0.68avg. 13F price*
At the end of Q2 2026, 8 institutions reported holding Zhengye Biotechnology-A (ZYBT) in their 13F filings, unchanged from Q1 2026. 1 opened new positions and 1 sold out. The largest holders were XTX Topco Ltd ($33K), Geode Capital Management, LLC ($20K) and WINTON GROUP Ltd ($9K).
- Company
- Zhengye Biotechnology-A
- CUSIP
- G989MS101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $93 |
| Exits | 1 | $5K |
All 13F filers, Q1 2026 → Q2 2026: 4,853 shares bought and 25,628 shares sold, net −20,775 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| XTX Topco Ltd | 0.00% | Add +10.7% | 48,865 | $33K |
| Geode Capital Management, LLC | 0.00% | No change | 29,068 | $20K |
| WINTON GROUP Ltd | 0.00% | Reduce -61.9% | 12,730 | $9K |
| UBS Group AG | 0.00% | Reduce -0.6% | 7,992 | $5K |
| Royal Bank of Canada | 0.00% | No change | 1,230 | $1K |
| Morgan Stanley | 0.00% | Reduce -5.0% | 248 | $168 |
| JPMorgan Chase & Co. | 0.00% | New | 134 | $93 |
| Caitong International Asset Management Co., Ltd | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is ZYBT's weight in each manager's 13F, not the share of Zhengye Biotechnology-A the manager owns.